Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Expects Exanta Experience To Benefit Future Anticoagulant R&D

Executive Summary

AstraZeneca's experience with its failed anticoagulant Exanta (ximelagatran) will provide the company an advantage going forward in developing new oral anticoagulants, VP and Cardiovascular Therapy Area Head Gunnar Olsson maintained

You may also be interested in...



Learning From Exanta: AstraZeneca Ready For Phase III With ‘0837

With its once-daily oral anticoagulant AZD0837 ready to move into Phase III, AstraZeneca is talking up the lessons it learned from its experience with the failed anticoagulantExanta (ximelagatran)

Learning From Exanta: AstraZeneca Ready For Phase III With ‘0837

With its once-daily oral anticoagulant AZD0837 ready to move into Phase III, AstraZeneca is talking up the lessons it learned from its experience with the failed anticoagulantExanta (ximelagatran)

Cardiovascular Biotech Misses MAb Era, Looks Ahead To Gene, Cell Therapy

Biotechnology R&D in cardiovascular disease slowed in the decade following the approval of the pioneering monoclonal antibody ReoPro, but emerging biotechnologies hold the potential for a resurgence of biologics amidst the small molecules that dominate the current CV pipeline

Related Content

UsernamePublicRestriction

Register

PS047288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel